NFKB1 and lung carcinoma: Clusterin inhibits TGFBR1 (transforming growth factor‐β receptor) from recruiting the TRAF6 (TNF receptor‐associated factor 6)/TAB2 (TAK1‐binding protein 2)/TAK1 complex, which leads to the activation of the TAK1/NF‐κB signalling pathways to block the progression of lung cancer.8